It’s been a rough few months for life-science IPOs, what with all the collapsed offerings and, often enough, miserable post-offering performance for those startups that have managed to inch their way across the finish line.
Yet the lure of the public markets remains strong, even with the Nasdaq down about 15 percent... (Read more)
Reprinted with permission from VentureBeat. Story copyright 2008 VentureBeat Inc. All rights reserved.
Post new comment